Serum Elafin and Vascular Affection in Behcet Disease

NCT06272929 | Not Yet Recruiting

• 1 other identifier: behcet and vascular
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity. To evaluate the vascular complications in BD and determine their relationship with disease activity. To assess the correlation between serum elafin and vascular affection and their relation with disease activity.

Conditions

Behcet Disease and Vascular Affection

Outcome Measures

Primary Outcomes (1)

• Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.

  Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.

  within one year

Study Arms (2)

45 patients with behcet disease

Device: doppler ultrasound

45 healthy participants

Device: doppler ultrasound

Interventions

doppler ultrasound DEVICE

doppler US

45 healthy participants; 45 patients with behcet disease

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed as BD. Age of all participants (20-45) years.

You may qualify if:

• Patients diagnosed as BD. Age of all participants (20-45) years.

You may not qualify if:

• Age \<20 or \>45 years. Other autoimmune diseases. Cardiovascular diseases (heart failure, myocardial ischemia). Possible related risk factors (e.g. diabetes, dyslipidemia, smoking). chronic conditions (e.g. chronic kidney disease, malignancy, autoimmune diseases).

Sponsors & Collaborators

• Assiut University: lead

Related Publications (3)

• Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet's disease: an update. Curr Opin Rheumatol. 2011 Jan;23(1):24-31. doi: 10.1097/BOR.0b013e3283410088.

  PMID: 21124084 BACKGROUND

• Kutlay A, Kose AA. Serum Elafin as a Potential Marker of Disease Activity in Behcet's Disease. Indian J Dermatol. 2023 Jul-Aug;68(4):372-376. doi: 10.4103/ijd.ijd_913_22.

  PMID: 37822392 BACKGROUND

• Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Behcet syndrome. Nat Rev Dis Primers. 2021 Sep 16;7(1):67. doi: 10.1038/s41572-021-00301-1.

  PMID: 34531393 BACKGROUND

MeSH Terms

Conditions

Behcet Syndrome

Interventions

Ultrasonography, Doppler

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases; Uveitis, Anterior; Panuveitis; Uveitis; Uveal Diseases; Eye Diseases; Vasculitis; Vascular Diseases; Cardiovascular Diseases; Hereditary Autoinflammatory Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vascular

Intervention Hierarchy (Ancestors)

Ultrasonography; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis

Central Study Contacts

Lobna Amer, MD

CONTACT

01019313530; lobnaamer20@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assiut

Study Record Dates

• First Submitted: February 16, 2024
• First Posted: February 22, 2024
• Study Start: March 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: April 1, 2025
• Last Updated: February 22, 2024

Record last verified: 2024-02